Channing Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-49,931
| Closed | -$9.22M | – | 110 |
|
|
2024
Q4 | $9.22M | Sell |
49,931
-676
| -1% | -$130K | 0.25% | 71 |
|
|
2024
Q3 | $9.97M | Buy |
50,607
+198
| +0.4% | +$41.1K | 0.25% | 67 |
|
|
2024
Q2 | $10.4M | Sell |
50,409
-355
| -0.7% | -$80.4K | 0.29% | 60 |
|
|
2024
Q1 | $13.8M | Hold |
50,764
| – | – | 0.37% | 47 |
|
|
2023
Q4 | $12M | Buy |
50,764
+1,205
| +2% | +$237K | 0.35% | 48 |
|
|
2023
Q3 | $9.71M | Buy |
49,559
+11,717
| +31% | +$2.41M | 0.32% | 54 |
|
|
2023
Q2 | $7.96M | Sell |
37,842
-11,412
| -23% | -$2.27M | 0.24% | 71 |
|
|
2023
Q1 | $9.94M | Sell |
49,254
-12,298
| -20% | -$2.79M | 0.32% | 66 |
|
|
2022
Q4 | $13.4M | Sell |
61,552
-392
| -0.6% | -$85.6K | 0.43% | 55 |
|
|
2022
Q3 | $12.2M | Buy |
61,944
+31,923
| +106% | +$6.89M | 0.42% | 47 |
|
|
2022
Q2 | $6.42M | Sell |
30,021
-18,415
| -38% | -$4.5M | 0.21% | 95 |
|
|
2022
Q1 | $13.8M | Buy |
48,436
+16,355
| +51% | +$5.04M | 0.41% | 54 |
|
|
2021
Q4 | $12.1M | Buy |
32,081
+5,834
| +22% | +$2.27M | 0.34% | 67 |
|
|
2021
Q3 | $10.8M | Sell |
26,247
-8,486
| -24% | -$3.52M | 0.34% | 74 |
|
|
2021
Q2 | $12.8M | Sell |
34,733
-6,595
| -16% | -$2.2M | 0.42% | 62 |
|
|
2021
Q1 | $12M | Buy |
41,328
+6,317
| +18% | +$1.76M | 0.41% | 69 |
|
|
2020
Q4 | $8.75M | Sell |
35,011
-3,534
| -9% | -$842K | 0.36% | 71 |
|
|
2020
Q3 | $8.73M | Sell |
38,545
-8,048
| -17% | -$1.67M | 0.47% | 52 |
|
|
2020
Q2 | $8.12M | Sell |
46,593
-230,180
| -83% | -$36.7M | 0.47% | 51 |
|
|
2020
Q1 | $34.9M | Sell |
276,773
-80,682
| -23% | -$12.1M | 2.47% | 6 |
|
|
2019
Q4 | $54.6M | Sell |
357,455
-14,888
| -4% | -$2.06M | 2.53% | 3 |
|
|
2019
Q3 | $49.3M | Sell |
372,343
-13,146
| -3% | -$1.76M | 2.28% | 6 |
|
|
2019
Q2 | $54.7M | Sell |
385,489
-77,781
| -17% | -$10.5M | 2.54% | 4 |
|
|
2019
Q1 | $67.3M | Sell |
463,270
-67,050
| -13% | -$8.81M | 3.1% | 2 |
|
|
2018
Q4 | $60M | Sell |
530,320
-136,295
| -20% | -$17.1M | 3.01% | 3 |
|
|
2018
Q3 | $89.7M | Sell |
666,615
-21,887
| -3% | -$2.7M | 3.23% | 1 |
|
|
2018
Q2 | $77.3M | Sell |
688,502
-13,081
| -2% | -$1.41M | 2.73% | 4 |
|
|
2018
Q1 | $74.9M | Buy |
701,583
+126,169
| +22% | +$13.6M | 2.62% | 7 |
|
|
2017
Q4 | $63M | Buy |
575,414
+88,549
| +18% | +$9.64M | 2.12% | 16 |
|
|
2017
Q3 | $52.6M | Sell |
486,865
-210,551
| -30% | -$21.6M | 1.98% | 22 |
|
|
2017
Q2 | $70.5M | Sell |
697,416
-129,076
| -16% | -$11.9M | 2.76% | 4 |
|
|
2017
Q1 | $74.3M | Sell |
826,492
-12,977
| -2% | -$1.1M | 2.71% | 4 |
|
|
2016
Q4 | $64M | Buy |
839,469
+152,344
| +22% | +$11.6M | 2.27% | 9 |
|
|
2016
Q3 | $57.3M | Buy |
687,125
+1,544
| +0.2% | +$129K | 2.28% | 8 |
|
|
2016
Q2 | $56.5M | Sell |
685,581
-5,930
| -0.9% | -$488K | 2.37% | 7 |
|
|
2016
Q1 | $52.5M | Buy |
691,511
+3,620
| +0.5% | +$268K | 2.34% | 9 |
|
|
2015
Q4 | $55.3M | Buy |
687,891
+115,587
| +20% | +$8.34M | 2.45% | 5 |
|
|
2015
Q3 | $36.4M | Buy |
572,304
+26,174
| +5% | +$1.88M | 1.77% | 21 |
|
|
2015
Q2 | $38.4M | Buy |
546,130
+6,721
| +1% | +$497K | 1.71% | 24 |
|
|
2015
Q1 | $42.8M | Buy |
539,409
+28,435
| +6% | +$2.1M | 1.95% | 20 |
|
|
2014
Q4 | $32.5M | Sell |
510,974
-30,301
| -6% | -$1.9M | 1.67% | 23 |
|
|
2014
Q3 | $32.3M | Buy |
541,275
+52,579
| +11% | +$3.01M | 1.95% | 5 |
|
|
2014
Q2 | $26.2M | Buy |
488,696
+111,409
| +30% | +$6.11M | 1.55% | 19 |
|
|
2014
Q1 | $22.8M | Sell |
377,287
-101,955
| -21% | -$5.94M | 1.45% | 26 |
|
|
2013
Q4 | $25.4M | Buy |
479,242
+28,762
| +6% | +$1.44M | 1.67% | 11 |
|
|
2013
Q3 | $20.8M | Buy |
450,480
+83,780
| +23% | +$3.84M | 1.53% | 15 |
|
|
2013
Q2 | $15M | Buy |
+366,700
| New | +$15.7M | 1.35% | 24 |
|
Other funds holding CRL
IC
Channing Capital Management's CRL Position: Q1 2025 in Review
Channing Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 49,931 shares — an estimated $9.22M sold.
Channing Capital Management first reported a position in CRL in Q2 2013 and held it in 47 quarters. The position peaked at $89.7M in Q3 2018. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2025.
- Channing Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
- Channing Capital Management sold 49,931 Charles River Laboratories shares in Q1 2025, an estimated $9.22M.
- Channing Capital Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 47 quarters.
- Channing Capital Management's Charles River Laboratories position peaked at $89.7M in Q3 2018.
- 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.
Based on Channing Capital Management's 13F filing for Q1 2025, filed 14 May 2025.